Compass Therapeutics Investor Presentation Deck

Phase 1a CTX-009 Monotherapy (all doses) Tumor Growth (%) 100 80 60 40 20 -20 -40 -60 -75% 48% 40% 39% COMPASS THERAPEUTICS 30% 23% 15% 15% 14% 10% 9% 9% 40 evaluable patients as of February 5, 2021 (All Phase 1 Patients, 0.3-17.5 mpk) 8% 8% 7% 7% 6% 4% 4% 4% 3% 3% 0.3 0.3 12.5 12.5 0.3 2.5 12.5 17.5 12.5 5.0 7.5 7.5 5.0 10.0 15.0 2.5 15.0 12.5 1.0 12.5 12.5 1.0 15.0 17.5 0% 0% 0% Patient (Dosage mpk) 12.5 0.3 5.0 -1% 10.0 5.0 12.5 7.5 1.0 -5% -5% -9% -9% -11% -13% -17% Gastric -20% CRC 2.5 7.5 10.0 12.5 15.0 10.0 12.5 10.0 Other -26% -27% -35% -38% -40% -41% 10

View entire presentation